UNSPSC 51401564: Loprazolam methanesulfonate

This classification denotes a benzodiazepine with the molecular formula C23H21ClN6O3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VKF8383J65, chemically known as 1h-imidazo(1,2-a)(1,4)benzodiazepin-1-one, 6-(2-chlorophenyl)-2,4-dihydro-2-((4-methyl-1-piperazinyl)methylene)-8-nitro-, (2z)-, methanesulfonate (1:1), but more generally known as loprazolam methanesulfonate, which bears US NIH Compound Identifier 3036679.

European Medicines Agency schedules loprazolam methanesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08576MIG. Most nations, for tariff purposes, schedule loprazolam methanesulfonate under HS 29335500. SMILES: CN1CCN(CC1)/C=C\2/C(=O)N3C4CCC(CC4C(=NCC3=N2)C5CCCCC5CL)[N+](=O)[O-].CS(=O)(=O)O.

UNSPSC 51401564 Loprazolam methanesulfonate is a Commodity code that currently shows little relevant recent activity aligned with its nominal scope. The three most recent state and local opportunities tagged under this code procure naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which are loprazolam methanesulfonate or closely related benzodiazepine therapeutics. The mismatch suggests that state and local procurement systems are applying this code to pharmaceutical procurement more broadly rather than to the specific active pharmaceutical ingredient the code nominally describes, making it difficult to isolate actual demand for loprazolam methanesulfonate at the state and local level based on recent solicitation activity.

The issuing bodies include a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS Commission), and a multistate cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and other participants). Geographic activity spans Florida, Texas, and the upper Midwest. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) for naloxone and drug deactivation systems through quarterly deliveries; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs; and MMCAP's S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers. Without a clear stream of loprazolam-specific solicitations, the code does not present a stable purchasing pattern for business development purposes under its stated commodity classification.